Splash Beverage Expands CannEpil into Veterinary Health, Diversifying into FDA-Regulated Pharma

What happened

Splash Beverage Group expanded its exclusive global license for CannEpil to include veterinary applications, creating a second FDA-regulated pharmaceutical development program. This move adds to the existing human CannEpil program and marks a strategic pivot into animal health. The expansion is based on the company's existing agreement with MGC Pharmaceuticals. While this creates a new potential revenue avenue, Splash's core beverage business remains deeply unprofitable and challenged. The initiative is early-stage and unproven, with no disclosed financial impact or timeline.

Implication

The pharma pivot introduces a speculative growth vector that could diversify away from struggling beverages, but it risks stretching already-thin resources. Investors should monitor for concrete regulatory milestones and funding, as failure to execute could accelerate cash burn. For now, the core thesis remains tied to beverage execution and balance-sheet stabilization.

Thesis delta

The previous thesis was exclusively about beverage platform execution. This news introduces a nascent pharmaceutical development program that could provide long-term optionality if successful. However, it does not alter the near-term risks of weak revenue, losses, and dilution. The burden of proof remains on beverage turnaround.